Merck Serono Announces Creation of First Spin-Off Company From Its Entrepreneur Partnership Program

We are really proud and satisfied that this first project is now coming to life. Through such initiatives, not only will we be able to maintain jobs in the Geneva area but also unique expertise,” said François Naef, Chairman of the Board of Directors of Merck Serono S.A. “The newly founded company will be headed by a highly experienced scientist and entrepreneur, which gives us a lot of confidence in the success of Prexton Therapeutics.

With a team composed of seasoned Merck Serono scientists with long standing experience in neurology and a significant portfolio of chemical compounds stemming from Merck Serono’s preclinical research, Prexton Therapeutics will be well positioned in the field of neurodegenerative diseases. The newly founded company will develop the mGluR programs from lead optimization up to clinical Phase I and seek partnership and licensing opportunities for further development. The company will be hosted in the offices and laboratory of Eclosion, a biotech start up incubator located in Plan les Ouates, Geneva, and supported by the Geneva authorities. Merck Serono will invest € 2.1 million as seed funding. Merck Serono Ventures will manage the investment and will be represented on the company’s board of directors.

“Metabotropic glutamate receptors (mGluR) have been shown recently to be a key target to tackle the onset of Parkinson’s disease. Therefore, modulating their response is certainly among the most promising ways to develop future treatments for one of the most severe brain diseases,” said François Conquet, founder and CEO of Prexton Therapeutics. “I have long been interested in the potential of mGluR targeted therapies and now there is a great opportunity to further develop Merck Serono’s programs in Parkinson’s disease and offer new hopes to patients.”

Announced in April 2012 in the framework of the efficiency measures being taken by Merck Serono, the Entrepreneur Partnership Program (EPP) is part of a € 30 million commitment to support the creation of spin off and start up companies focused on continuing activities and compounds that originated at Merck Serono. This program is aimed at reducing the impact on employment following closure of the Geneva headquarters due to the restructuring.

Media Contact:
Merck Serono International S.A. Chemin des Mines 9 Case Postale 54 1211 Genève GE Tel: +41 22 414 30 00 Fax: +41 22 414 21 79

Editor's note: Image rights belong to the respective publisher.